Aytu BioPharma (AYTU)
(Delayed Data from NSDQ)
$2.86 USD
+0.05 (1.78%)
Updated Apr 30, 2024 11:06 AM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
AYTU 2.86 +0.05(1.78%)
Will AYTU be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for AYTU based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AYTU
ANI Pharmaceuticals (ANIP) Beats Q1 Earnings and Revenue Estimates
Aytu BioPharma Inc. (AYTU) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
AYTU: What are Zacks experts saying now?
Zacks Private Portfolio Services
Bears are Losing Control Over Aytu BioPharma Inc. (AYTU), Here's Why It's a 'Buy' Now
Other News for AYTU
Aytu BioPharma to Present at the Emerging Growth Conference on April 4, 2024
Presenting on the Emerging Growth Conference 69 Day 2 on April 4 Register Now
Maxim Group Remains a Buy on Aytu BioScience (AYTU)
Aytu BioPharma, Inc. (AYTU) Q2 2024 Earnings Call Transcript
Earnings Scheduled For February 14, 2024